359 related articles for article (PubMed ID: 27854508)
1. New and Repurposed Drugs for Pediatric Multidrug-Resistant Tuberculosis. Practice-based Recommendations.
Harausz EP; Garcia-Prats AJ; Seddon JA; Schaaf HS; Hesseling AC; Achar J; Bernheimer J; Cruz AT; D'Ambrosio L; Detjen A; Graham SM; Hughes J; Jonckheere S; Marais BJ; Migliori GB; McKenna L; Skrahina A; Tadolini M; Wilson P; Furin J;
Am J Respir Crit Care Med; 2017 May; 195(10):1300-1310. PubMed ID: 27854508
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes Among Pediatric Patients With Highly Drug-Resistant Tuberculosis: The Role of New and Repurposed Second-Line Tuberculosis Drugs.
Madzgharashvili T; Salindri AD; Magee MJ; Tukvadze N; Avaliani Z; Blumberg HM; Kempker RR; Lomtadze N
J Pediatric Infect Dis Soc; 2021 Apr; 10(4):457-467. PubMed ID: 33347564
[TBL] [Abstract][Full Text] [Related]
3. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.
Wirth D; Dass R; Hettle R
BMC Health Serv Res; 2017 Mar; 17(1):182. PubMed ID: 28270207
[TBL] [Abstract][Full Text] [Related]
5. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
[TBL] [Abstract][Full Text] [Related]
6. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB?
Dheda K; Cox H; Esmail A; Wasserman S; Chang KC; Lange C
Respirology; 2018 Jan; 23(1):36-45. PubMed ID: 28850767
[TBL] [Abstract][Full Text] [Related]
7. New drugs and perspectives for new anti-tuberculosis regimens.
Tiberi S; Muñoz-Torrico M; Duarte R; Dalcolmo M; D'Ambrosio L; Migliori GB
Pulmonology; 2018; 24(2):86-98. PubMed ID: 29487031
[TBL] [Abstract][Full Text] [Related]
8. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
Centers for Disease Control and Prevention
MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
[TBL] [Abstract][Full Text] [Related]
9. Additional Drug Resistance in Patients with Multidrug-resistant Tuberculosis in Korea: a Multicenter Study from 2010 to 2019.
Lee T; Lee SJ; Jeon D; Lee HY; Kim HJ; Kang BH; Mok J
J Korean Med Sci; 2021 Jul; 36(26):e174. PubMed ID: 34227261
[TBL] [Abstract][Full Text] [Related]
10. Multidrug-resistant tuberculosis in children and adolescents: current strategies for prevention and treatment.
Seddon JA; Johnson S; Palmer M; van der Zalm MM; Lopez-Varela E; Hughes J; Schaaf HS
Expert Rev Respir Med; 2021 Feb; 15(2):221-237. PubMed ID: 32965141
[TBL] [Abstract][Full Text] [Related]
11. Therapy of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis.
Seaworth BJ; Griffith DE
Microbiol Spectr; 2017 Mar; 5(2):. PubMed ID: 28361737
[TBL] [Abstract][Full Text] [Related]
12. Shortened tuberculosis treatment regimens: what is new?
Silva DR; Mello FCQ; Migliori GB
J Bras Pneumol; 2020; 46(2):e20200009. PubMed ID: 32215450
[TBL] [Abstract][Full Text] [Related]
13. (Re)moving the needle: prospects for all-oral treatment for multidrug-resistant tuberculosis.
Milstein M; Brzezinski A; Varaine F; Mitnick CD
Int J Tuberc Lung Dis; 2016 Dec; 20(12):18-23. PubMed ID: 28240568
[TBL] [Abstract][Full Text] [Related]
14. Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis.
Dheda K; Chang KC; Guglielmetti L; Furin J; Schaaf HS; Chesov D; Esmail A; Lange C
Clin Microbiol Infect; 2017 Mar; 23(3):131-140. PubMed ID: 27756712
[TBL] [Abstract][Full Text] [Related]
15. Current status of pharmacokinetic and safety studies of multidrug-resistant tuberculosis treatment in children.
Garcia-Prats AJ; Svensson EM; Weld ED; Schaaf HS; Hesseling AC
Int J Tuberc Lung Dis; 2018 May; 22(5):15-23. PubMed ID: 29665949
[TBL] [Abstract][Full Text] [Related]
16. New Drugs and Regimens for Tuberculosis Disease Treatment in Children and Adolescents.
Garcia-Prats AJ; Starke JR; Waning B; Kaiser B; Seddon JA
J Pediatric Infect Dis Soc; 2022 Oct; 11(Supplement_3):S101-S109. PubMed ID: 36314547
[TBL] [Abstract][Full Text] [Related]
17. The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens.
Khan U; Huerga H; Khan AJ; Mitnick CD; Hewison C; Varaine F; Bastard M; Rich M; Franke MF; Atwood S; Khan PY; Seung KJ
BMC Infect Dis; 2019 Aug; 19(1):733. PubMed ID: 31429722
[TBL] [Abstract][Full Text] [Related]
18. Diagnosis and Management of Multidrug-Resistant Tuberculosis in Children: A Practical Approach.
Schaaf HS
Indian J Pediatr; 2019 Aug; 86(8):717-724. PubMed ID: 30656560
[TBL] [Abstract][Full Text] [Related]
19. Applicability of the shorter 'Bangladesh regimen' in high multidrug-resistant tuberculosis settings.
Sotgiu G; Tiberi S; Centis R; D'Ambrosio L; Fuentes Z; Zumla A; Migliori GB
Int J Infect Dis; 2017 Mar; 56():190-193. PubMed ID: 27816662
[TBL] [Abstract][Full Text] [Related]
20. Delamanid: From discovery to its use for pulmonary multidrug-resistant tuberculosis (MDR-TB).
Liu Y; Matsumoto M; Ishida H; Ohguro K; Yoshitake M; Gupta R; Geiter L; Hafkin J
Tuberculosis (Edinb); 2018 Jul; 111():20-30. PubMed ID: 30029909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
